Genelux (GNLX) EBITDA (2022 - 2026)

Genelux's EBITDA history runs 5 years deep, the most recent figure standing at -$9.2 million for Q1 2026.

• On a quarterly basis, EBITDA fell 17.34% year-over-year to -$9.2 million in Q1 2026; TTM through Mar 2026 was -$34.6 million, a 10.1% decrease from a year earlier, with the FY2025 full-year figure at -$33.2 million, down 4.79% from the prior year.
• EBITDA rose to -$9.2 million in Q1 2026 per GNLX's latest filing, from -$9.4 million in the prior quarter.
• Across five years, EBITDA topped out at $6.3 million in Q3 2022 and bottomed at -$9.7 million in Q4 2024.
• The 5-year median for EBITDA is -$7.0 million (2023), against an average of -$6.3 million.
• Across the five-year window, EBITDA slumped 183.65% in 2023 and grew 3.68% in 2025, its largest moves.
• Year by year, EBITDA stood at -$3.1 million in 2022, then slumped by 126.28% to -$7.0 million in 2023, then tumbled by 39.24% to -$9.7 million in 2024, then grew by 3.45% to -$9.4 million in 2025, then climbed by 2.56% to -$9.2 million in 2026.
• Per Business Quant, the three latest GNLX EBITDA figures stand at -$9.2 million (Q1 2026), -$9.4 million (Q4 2025), and -$8.2 million (Q3 2025).